Neuroendocrine carcinoma · 2 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and Etoposide (EP) Variant #22 | — | R 1 819 | 21d | — | ~12.5 mo | ~6 | ~R 10 916 PFS proxy · indirect | 1 |
Cisplatin and Irinotecan (IC) Variant #01 | — | R 1 795 | 21d | — | ~10.9 mo | ~2 | ~R 3 591 PFS proxy · indirect | 1 |
2 of 2 regimens shown